Your browser doesn't support javascript.
loading
Outcomes and Attributes Patients Value When Choosing Glucose-Lowering Medications: A Mixed-Methods Study.
Golembiewski, Elizabeth H; Garcia Bautista, Andrea E; Polley, Eric; Umpierrez, Guillermo E; Galindo, Rodolfo J; Brito, Juan P; Montori, Victor M; Gockerman, Janet P; Tesulov, Michael; Labatte, Bertina; Mickelson, Mindy M; McCoy, Rozalina G.
Afiliação
  • Golembiewski EH; Knowledge and Evaluation Research (KER) Unit, Mayo Clinic, Rochester, MN.
  • Garcia Bautista AE; Knowledge and Evaluation Research (KER) Unit, Mayo Clinic, Rochester, MN.
  • Polley E; Department of Public Health Sciences, University of Chicago, Chicago, IL.
  • Umpierrez GE; Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
  • Galindo RJ; Division of Endocrinology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL.
  • Brito JP; Knowledge and Evaluation Research (KER) Unit, Mayo Clinic, Rochester, MN.
  • Montori VM; Division of Endocrinology, Department of Medicine, Mayo Clinic, Rochester, MN.
  • Gockerman JP; Knowledge and Evaluation Research (KER) Unit, Mayo Clinic, Rochester, MN.
  • Tesulov M; Division of Endocrinology, Department of Medicine, Mayo Clinic, Rochester, MN.
  • Labatte B; Patient investigator, Grand Rapids, MI.
  • Mickelson MM; Patient investigator, Rochester, MN.
  • McCoy RG; Patient investigator, Rochester, MN.
Clin Diabetes ; 42(3): 371-387, 2024.
Article em En | MEDLINE | ID: mdl-39015157
ABSTRACT
This mixed-methods study sought to identify pharmacotherapy preferences among 40 noninsulin-treated adults with type 2 diabetes receiving care at two U.S. health care systems. Participants ranked by relative importance various health outcomes and medication attributes and then contextualized their rankings. Most participants ranked blindness (63%), death (60%), heart attack (48%), and heart failure (48%) as the most important health outcomes and glucose-lowering efficacy (68%) as the most important medication attribute, followed by oral administration (45%) and lack of gastrointestinal side effects (38%).

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article